Elekta Acquires iCAD’s Xoft Brachytherapy Business for $5.5 Million

Elekta has acquired iCAD’s Xoft brachytherapy business for approximately $5.5 million plus assumed liabilities.

The acquisition of the Xoft Axxent Electronic Brachytherapy (eBx) System will enable Elekta to offer electronic brachytherapy technology and provide an expanded range of cancer treatment options.

Xoft’s unique technology, which uses a miniaturized low energy X-ray source instead of a radioactive isotope, can be used in a variety of clinical settings with minimal shielding. It is currently used primarily for intraoperative treatment of breast cancer, non-melanoma skin cancer, and gynecological cancers, giving physicians the confidence to accurately and effectively treat cancer and enable patients to lead healthy, quality lives.

FDA cleared and CE marked, the Xoft System has been installed in more than 120 sites in 16 countries and licensed in a growing number of countries, supported by a growing body of evidence for the treatment of early-stage breast cancer, non-melanoma skin cancer (NMSC), gynecological cancers, and brain cancers.

The Xoft technology will now be able to reach more patients in need of personalized, precision radiation therapy through Elekta’s global network in more than 120 countries.

To view the source version, please click HERE.

en_GBEnglish (UK)